BG97519A - Метод за получаване на ваксина срещу вируса на човешка имунна недостатъчност - Google Patents

Метод за получаване на ваксина срещу вируса на човешка имунна недостатъчност Download PDF

Info

Publication number: BG97519A
Authority: BG; Bulgaria
Prior art keywords: vaccine; hiv; protein; recombinant; patients
Prior art date: 1991-06-11

Application number

BG97519A

Other languages

Bulgarian (bg)

English (en)

Inventor

Gale Smith

Franklin Volvovitz

Original Assignee

Microgenesys Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-06-11

Filing date

1993-03-10

Publication date

1994-03-24

1993-03-10 Application filed by Microgenesys Inc. filed Critical Microgenesys Inc.

1994-03-24 Publication of BG97519A publication Critical patent/BG97519A/bg

Links

238000000034 method Methods 0.000 title claims description 27
229960005486 vaccine Drugs 0.000 title abstract description 75
108090000623 proteins and genes Proteins 0.000 claims abstract description 59
102000004169 proteins and genes Human genes 0.000 claims abstract description 36
241000701447 unidentified baculovirus Species 0.000 claims abstract description 17
239000002671 adjuvant Substances 0.000 claims abstract description 15
241000238631 Hexapoda Species 0.000 claims abstract description 10
239000013598 vector Substances 0.000 claims abstract description 3
229940033330 HIV vaccine Drugs 0.000 claims abstract 2
229940037003 alum Drugs 0.000 claims description 23
150000001413 amino acids Chemical class 0.000 claims description 21
101710091045 Envelope protein Proteins 0.000 claims description 20
101710188315 Protein X Proteins 0.000 claims description 20
239000002245 particle Substances 0.000 claims description 20
108090001090 Lectins Proteins 0.000 claims description 9
102000004856 Lectins Human genes 0.000 claims description 9
239000000872 buffer Substances 0.000 claims description 9
239000002523 lectin Substances 0.000 claims description 9
108010034897 lentil lectin Proteins 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
238000005406 washing Methods 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
230000008569 process Effects 0.000 claims description 3
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
238000000926 separation method Methods 0.000 claims description 2
102100021696 Syncytin-1 Human genes 0.000 claims 5
108010026552 Proteome Proteins 0.000 claims 1
241000555745 Sciuridae Species 0.000 claims 1
229940070376 protein Drugs 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 32
241000700605 Viruses Species 0.000 abstract description 15
238000012360 testing method Methods 0.000 abstract description 15
241001465754 Metazoa Species 0.000 abstract description 14
230000003612 virological effect Effects 0.000 abstract description 12
230000002163 immunogen Effects 0.000 abstract description 9
230000028993 immune response Effects 0.000 abstract description 8
208000030507 AIDS Diseases 0.000 abstract description 6
230000024932 T cell mediated immunity Effects 0.000 abstract description 6
108010003533 Viral Envelope Proteins Proteins 0.000 abstract description 4
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract description 4
238000010367 cloning Methods 0.000 abstract description 4
238000000338 in vitro Methods 0.000 abstract description 4
210000000987 immune system Anatomy 0.000 abstract description 3
210000004779 membrane envelope Anatomy 0.000 abstract description 3
108010052285 Membrane Proteins Proteins 0.000 abstract 2
102000018697 Membrane Proteins Human genes 0.000 abstract 2
238000002560 therapeutic procedure Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 42
208000031886 HIV Infections Diseases 0.000 description 35
210000002966 serum Anatomy 0.000 description 29
239000000427 antigen Substances 0.000 description 28
102000036639 antigens Human genes 0.000 description 28
108091007433 antigens Proteins 0.000 description 28
241000725303 Human immunodeficiency virus Species 0.000 description 27
230000004044 response Effects 0.000 description 24
230000003053 immunization Effects 0.000 description 18
238000002649 immunization Methods 0.000 description 18
241000699670 Mus sp. Species 0.000 description 16
238000002347 injection Methods 0.000 description 16
239000007924 injection Substances 0.000 description 16
238000002255 vaccination Methods 0.000 description 16
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 15
239000000243 solution Substances 0.000 description 15
208000015181 infectious disease Diseases 0.000 description 13
239000000499 gel Substances 0.000 description 12
238000010790 dilution Methods 0.000 description 11
239000012895 dilution Substances 0.000 description 11
230000005847 immunogenicity Effects 0.000 description 11
230000009696 proliferative response Effects 0.000 description 11
230000005875 antibody response Effects 0.000 description 10
230000003472 neutralizing effect Effects 0.000 description 10
238000000746 purification Methods 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 9
230000001413 cellular effect Effects 0.000 description 9
238000005755 formation reaction Methods 0.000 description 8
239000012634 fragment Substances 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
230000008859 change Effects 0.000 description 7
229940009976 deoxycholate Drugs 0.000 description 7
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 7
210000000981 epithelium Anatomy 0.000 description 7
238000002523 gelfiltration Methods 0.000 description 7
101710205625 Capsid protein p24 Proteins 0.000 description 6
108020004705 Codon Proteins 0.000 description 6
101710177166 Phosphoprotein Proteins 0.000 description 6
101710149279 Small delta antigen Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000006386 neutralization reaction Methods 0.000 description 6
229940124718 AIDS vaccine Drugs 0.000 description 5
108090000288 Glycoproteins Proteins 0.000 description 5
102000003886 Glycoproteins Human genes 0.000 description 5
208000037357 HIV infectious disease Diseases 0.000 description 5
241000282560 Macaca mulatta Species 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
230000008348 humoral response Effects 0.000 description 5
239000000463 material Substances 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
238000011282 treatment Methods 0.000 description 5
241000282577 Pan troglodytes Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
230000036755 cellular response Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
241000283707 Capra Species 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000282579 Pan Species 0.000 description 3
101800001690 Transmembrane protein gp41 Proteins 0.000 description 3
239000012190 activator Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000013256 coordination polymer Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000001641 gel filtration chromatography Methods 0.000 description 3
238000010166 immunofluorescence Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
208000006820 Arthralgia Diseases 0.000 description 2
108700010908 HIV-1 proteins Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 2
208000008771 Lymphadenopathy Diseases 0.000 description 2
208000005647 Mumps Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
241000237502 Ostreidae Species 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000036737 immune function Effects 0.000 description 2
229940124622 immune-modulator drug Drugs 0.000 description 2
230000036039 immunity Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
208000018555 lymphatic system disease Diseases 0.000 description 2
208000010805 mumps infectious disease Diseases 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
235000020636 oyster Nutrition 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
238000000527 sonication Methods 0.000 description 2
241000894007 species Species 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000005924 vaccine-induced immune response Effects 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
PFFIDZXUXFLSSR-UHFFFAOYSA-N 1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound S1C=CC(NC(=O)C=2C(=NN(C)C=2)C(F)(F)F)=C1C(C)CC(C)C PFFIDZXUXFLSSR-UHFFFAOYSA-N 0.000 description 1
102100036962 5'-3' exoribonuclease 1 Human genes 0.000 description 1
241000208140 Acer Species 0.000 description 1
241001143500 Aceraceae Species 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000132028 Bellis Species 0.000 description 1
240000007124 Brassica oleracea Species 0.000 description 1
235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
102100021984 C-C motif chemokine 4-like Human genes 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000008374 Capirona Species 0.000 description 1
235000002568 Capsicum frutescens Nutrition 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000218645 Cedrus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
101710187001 DNA terminal protein Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
101000804879 Homo sapiens 5'-3' exoribonuclease 1 Proteins 0.000 description 1
101000777471 Homo sapiens C-C motif chemokine 4 Proteins 0.000 description 1
101000737602 Homo sapiens Ceramide synthase 1 Proteins 0.000 description 1
DTRYYPKLEYYJTH-UHFFFAOYSA-N I.OP(O)(O)=O Chemical compound I.OP(O)(O)=O DTRYYPKLEYYJTH-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000692870 Inachis io Species 0.000 description 1
241000219739 Lens Species 0.000 description 1
240000004322 Lens culinaris Species 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
101800000135 N-terminal protein Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101800001452 P1 proteinase Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282376 Panthera tigris Species 0.000 description 1
-1 Pentyl lactin Chemical compound 0.000 description 1
101710182846 Polyhedrin Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
101100397220 Rhodococcus sp. (strain AD45) isoH gene Proteins 0.000 description 1
101150071661 SLC25A20 gene Proteins 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
206010039740 Screaming Diseases 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
241000863032 Trieres Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000798 anti-retroviral effect Effects 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
101150102633 cact gene Proteins 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
210000001061 forehead Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000005858 glycosidation reaction Methods 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
230000012010 growth Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
239000000568 immunological adjuvant Substances 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000004969 ion scattering spectroscopy Methods 0.000 description 1
230000007803 itching Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
235000021190 leftovers Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
238000009527 percussion Methods 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
230000002516 postimmunization Effects 0.000 description 1
238000009021 pre-vaccination Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
235000021251 pulses Nutrition 0.000 description 1
101150002764 purA gene Proteins 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
101150076141 rn gene Proteins 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000009958 sewing Methods 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
JAEKEOGDGMUJNX-UHFFFAOYSA-J sodium trichloroalumane acetate Chemical compound C(C)(=O)[O-].[Na+].[Al](Cl)(Cl)Cl JAEKEOGDGMUJNX-UHFFFAOYSA-J 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BG97519A 1991-06-11 1993-03-10 Метод за получаване на ваксина срещу вируса на човешка имунна недостатъчност BG97519A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US71415291A	1991-06-11	1991-06-11
PCT/US1992/004980 WO1992022654A1 (en)	1991-06-11	1992-06-10	Vaccine and treatment method of human immunodeficiency virus infection

Publications (1)

Publication Number	Publication Date
BG97519A true BG97519A (bg)	1994-03-24

Family

ID=24868938

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG97519A BG97519A (bg)	1991-06-11	1993-03-10	Метод за получаване на ваксина срещу вируса на човешка имунна недостатъчност

Country Status (18)

Country	Link
EP (1)	EP0542998A1 (et)
JP (1)	JPH06501851A (et)
CN (1)	CN1068266A (et)
AU (2)	AU2193192A (et)
BG (1)	BG97519A (et)
CA (1)	CA2087732A1 (et)
EE (1)	EE9400183A (et)
FI (1)	FI930577L (et)
HU (1)	HUT68355A (et)
IE (1)	IE921875A1 (et)
IL (1)	IL102092A (et)
LT (1)	LT3365B (et)
MX (1)	MX9202781A (et)
PL (1)	PL297849A1 (et)
PT (1)	PT100584A (et)
SK (1)	SK18993A3 (et)
WO (1)	WO1992022654A1 (et)
ZA (1)	ZA924150B (et)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE40786E1 (en) *	1984-03-16	2009-06-23	The United States Of America As Represented By The Secretary Of The Army	Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6017536A (en) *	1993-06-07	2000-01-25	Trimeris, Inc.	Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) *	1993-06-07	1995-11-07	Duke University	Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en)	1993-06-07	2002-11-12	Trimeris, Inc.	Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
WO1995017515A1 (en) *	1993-12-23	1995-06-29	University Technologies International Inc.	Methods of expressing proteins in insect cells and methods of killing insects
AU723537B2 (en)	1995-06-07	2000-08-31	Trimeris Inc.	The treatment of HIV and other viral infections using combinatorial therapy
US6395541B1 (en)	1996-05-23	2002-05-28	The Rockefeller University	Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en)	1996-06-24	2001-11-20	University Of Maryland Biotechnology Institute	Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) *	1996-11-27	2000-06-20	Emory University	Virus-like particles, methods and immunogenic compositions
US6214540B1 (en)	1997-03-26	2001-04-10	University Of Maryland Biotechnology Institute	Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en)	1997-06-24	2003-06-24	Robert C. Gallo	Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en)	1997-09-16	2003-04-15	BIOMéRIEUX, INC.	Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en)	1999-07-09	2004-06-15	Trimeris, Inc.	Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en)	1999-08-06	2011-08-09	Nobel Biosciences Llc	Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en)	2000-02-29	2003-09-23	Trimeris, Inc.	Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en)	2002-02-20	2002-03-14	Immunaid Pty Ltd	Strategy for retroviral immunotherapy
JP2006509039A (ja) *	2002-12-03	2006-03-16	ユニバーシティオブマサチューセッツ	多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
PL1692516T3 (pl)	2003-10-24	2011-05-31	Immunaid Pty Ltd	Sposób terapii
GT200800303A (es)	2007-12-24	2009-09-18		Combinacion anti-retroviral
PT2435825E (pt)	2009-05-27	2015-11-02	Biotempus Ltd	Métodos para o tratamento de doenças
AU2012298125B2 (en)	2011-08-19	2015-09-24	Immortal Spirit Limited	Antibody and antibody-containing composition
CN102961760B (zh) *	2011-09-01	2017-07-18	常州文松生物技术有限公司	重叠肽作为制备皮肤试验和检测特异性细胞免疫的试剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL89118A0 (en) *	1988-02-03	1989-08-15	Microgenesys Inc	Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

1992
- 1992-06-03 IL IL10209292A patent/IL102092A/en not_active IP Right Cessation
- 1992-06-08 ZA ZA924150A patent/ZA924150B/xx unknown
- 1992-06-10 HU HU9300686A patent/HUT68355A/hu unknown
- 1992-06-10 JP JP5501040A patent/JPH06501851A/ja active Pending
- 1992-06-10 WO PCT/US1992/004980 patent/WO1992022654A1/en not_active Ceased
- 1992-06-10 SK SK18993A patent/SK18993A3/sk unknown
- 1992-06-10 AU AU21931/92A patent/AU2193192A/en not_active Abandoned
- 1992-06-10 EP EP92913889A patent/EP0542998A1/en not_active Withdrawn
- 1992-06-10 MX MX9202781A patent/MX9202781A/es unknown
- 1992-06-10 CA CA002087732A patent/CA2087732A1/en not_active Abandoned
- 1992-06-10 FI FI930577A patent/FI930577L/fi not_active Application Discontinuation
- 1992-06-10 PL PL29784992A patent/PL297849A1/xx unknown
- 1992-06-11 CN CN92104517A patent/CN1068266A/zh active Pending
- 1992-06-11 PT PT100584A patent/PT100584A/pt not_active Application Discontinuation
- 1992-07-01 IE IE187592A patent/IE921875A1/en not_active Application Discontinuation
1993
- 1993-02-11 LT LTIP335A patent/LT3365B/lt not_active IP Right Cessation
- 1993-03-10 BG BG97519A patent/BG97519A/bg unknown
1994
- 1994-09-21 EE EE9400183A patent/EE9400183A/et unknown
1995
- 1995-12-07 AU AU40288/95A patent/AU4028895A/en not_active Abandoned

Also Published As

Publication number	Publication date
SK18993A3 (en)	1993-10-06
FI930577A7 (fi)	1993-03-24
MX9202781A (es)	1993-04-01
HU9300686D0 (en)	1993-06-28
IL102092A0 (en)	1993-01-14
AU4028895A (en)	1996-02-22
EE9400183A (et)	1995-12-15
HUT68355A (en)	1995-06-28
LTIP335A (en)	1995-01-31
AU2193192A (en)	1993-01-12
LT3365B (en)	1995-07-25
PL297849A1 (en)	1994-01-24
JPH06501851A (ja)	1994-03-03
IL102092A (en)	1996-11-14
ZA924150B (en)	1993-02-24
PT100584A (pt)	1993-07-30
FI930577A0 (fi)	1993-02-10
IE921875A1 (en)	1992-12-16
CA2087732A1 (en)	1992-12-12
FI930577L (fi)	1993-03-24
WO1992022654A1 (en)	1992-12-23
EP0542998A1 (en)	1993-05-26
CN1068266A (zh)	1993-01-27

Publication	Publication Date	Title
BG97519A (bg)	1994-03-24	Метод за получаване на ваксина срещу вируса на човешка имунна недостатъчност
US12233124B2 (en)	2025-02-25	Recombinant metapneumovirus f proteins and their use
Gorse et al.	1996	A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine
EP0939835A1 (en)	1999-09-08	Compositions and methods for treating viral infections
CN108912215A (zh)	2018-11-30	用于登革病毒表位的方法和组合物
JP2013523617A (ja)	2013-06-17	Ｈｉｖワクチン
CZ195793A3 (en)	1994-05-18	Derivatives gp160 and vaccine based on gp160 or on a derivative of said substance, containing an auxiliary component
KR100194079B1 (ko)	1999-06-15	Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법
US9486518B2 (en)	2016-11-08	Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine
EP0327180A2 (en)	1989-08-09	Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
AU733234B2 (en)	2001-05-10	Conjugated peptides, immunological reagent containing same and use thereof for treatment of immunological disorders
WO2025189435A1 (zh)	2025-09-18	针对猫fipv的多表位抗原构建rna疫苗的方法
DE69233271T2 (de)	2004-09-09	Therapeutischer- und präventivimpfstoff gegen hiv
EP0328390B1 (en)	1994-09-14	Peptide treatment of refractory infectious diseases
US20080267989A1 (en)	2008-10-30	Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens
US7588764B2 (en)	2009-09-15	Compositions comprising human immunodeficiency virus Tat adsorbed to the surface of anionic nanoparticles
US20210379182A1 (en)	2021-12-09	Bivalent dengue/hepatitis b vaccines
JP2001505763A (ja)	2001-05-08	Ｈｉｖｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
AU2006200454B2 (en)	2008-05-08	Compositions and methods for treating viral infections
WO2025090742A1 (en)	2025-05-01	Coronavirus receptor binding domain (rbd) nanoparticle vaccines
SI9200420A (sl)	1994-09-30	Vakcina proti infekciji, ki jo povzroča človeški virus imunodeficience
HU211505A9 (hu)	1995-11-28	HIV-fertőzés kezelésére szolgáló vakcinakészítmény Az átmeneti oltalom az 1-15. igénypontokra vonatkozik.
LV10492B (en)	1995-08-20	Vaccine and treatment method for human immunodeficiency virus
HK1128410A (en)	2009-10-30	Multivalent hiv vaccines
HRP921484A2 (en)	1994-12-31	Vaccine and treatment method of human immunodeficiency virus infection